Xentria, Inc.
Tom Hoggan is an experienced professional in the biotechnology and clinical research sectors, currently serving as Director at Hoggan Biotech Consulting and Portfolio Development & Strategy Consultant at Xentria, Inc. Since March 2022, Tom has been providing consulting services focused on clinical development, commercial strategy, and resource planning. Previously, from 2014 to 2022, Tom held various leadership roles at Parexel, including Director of Integrated Solutions Strategy, where expertise was applied to develop competitive strategies for immunology and inflammation markets. Earlier experience includes positions at the NIHR Clinical Research Network and ICON plc, demonstrating a strong background in recruitment, feasibility assessment, and strategic management in clinical trials. Tom holds a Graduate Certificate in Management from The University of Salford.
This person is not in any offices
Xentria, Inc.
Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families. Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership. We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.